CSF2 and COVID-19: With few specific treatments approved for COVID-19 other than dexamethasone, we conclude that trials targeting the generation of immature neutrophils, for example by inhibiting the actions of GM-CSF, or improving the removal of cfDNA using gelsolin or AIR DNaseTM offer novel and rational approaches to reducing the severity of COVID-19 symptoms.